Literature DB >> 2643034

Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum.

D C Kaslow1, I A Quakyi, D B Keister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2643034     DOI： 10.1016/0166-6851(89)90134-5

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN： 0166-6851            Impact factor:   1.759


× No keyword cloud information.
  20 in total

1.  Malaria, mosquitoes and the legacy of Ronald Ross.

Authors:  Robert E Sinden
Journal:  Bull World Health Organ       Date:  2007-11       Impact factor: 9.408

2.  Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum.

Authors:  A A Escalante; A A Lal; F J Ayala
Journal:  Genetics       Date:  1998-05       Impact factor: 4.562

3.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

4.  The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.

Authors:  Lediya Cheru; Yimin Wu; Ababacar Diouf; Samuel E Moretz; Olga V Muratova; Guanhong Song; Michael P Fay; Louis H Miller; Carole A Long; Kazutoyo Miura
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 5.  Advances and challenges in malaria vaccine development.

Authors:  Peter D Crompton; Susan K Pierce; Louis H Miller
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

6.  Maternal immunization with gametocyte antigens as a means of providing protective immunity against Eimeria maxima in chickens.

Authors:  M Wallach; A Halabi; G Pillemer; O Sar-Shalom; D Mencher; M Gilad; U Bendheim; H D Danforth; P C Augustine
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

7.  Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Authors:  H Hisaeda; A W Stowers; T Tsuboi; W E Collins; J S Sattabongkot; N Suwanabun; M Torii; D C Kaslow
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

8.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

9.  Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection.

Authors:  Takeshi Arakawa; Mayumi Tachibana; Takeshi Miyata; Tetsuya Harakuni; Hideyasu Kohama; Yasunobu Matsumoto; Naotoshi Tsuji; Hajime Hisaeda; Anthony Stowers; Motomi Torii; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

10.  Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds.

Authors:  Dari F Da; Saurabh Dixit; Jetsumon Sattabonkot; Jianbing Mu; Luc Abate; Bhanumati Ramineni; Jean Bosco Ouedraogo; Nicholas J MacDonald; Michael P Fay; Xin-zhuan Su; Anna Cohuet; Yimin Wu
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.